Breakfast News: A Conversation With Ionis CEO

Ionis Pharmaceuticals CEO Brett Monia discusses the company's progress in 2026, highlighting FDA approval for Tryngolza and upcoming results for Pelacarsen in heart disease treatment. The company targets cash flow break-even in 2028 and projects $7 billion in peak revenue from late-stage programs. With 13 neurology drugs in clinical trials, Ionis aims to establish itself as a leader in antisense technology beyond first-mover competitors.

08/22/2026, 7:30 AM • The Motley Fool

Precision Medicine Collaboration and Licensing Deals 2019-2026 | Gain Access to Over 1,350 Deals and Benchmark with Confidence

ResearchAndMarkets.com released a comprehensive report analyzing 1,350+ precision medicine collaboration and licensing deals from 2019-2026. The report provides detailed benchmarking data on deal structures, financial terms, and contract provisions to support business development and strategy decisions in the precision medicine sector.

08/07/2026, 5:56 AM • GlobeNewswire

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

BioAge Labs announced the first participant dosing in QUELL-CV, a Phase 2 trial of BGE-102, an oral NLRP3 inhibitor for patients with obesity and elevated inflammation. Phase 1 data showed BGE-102 achieved up to 98% suppression of IL-1β and 86% median hsCRP reductions. The company also plans to initiate QUELL-DME trial in diabetic macular edema in mid-2026. BioAge reported Q2 2026 net loss of $26.1 million with $381.3 million in cash, sufficient to fund operations through 2029.

08/05/2026, 4:50 PM • GlobeNewswire

Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating

Cathie Wood's Ark Investment Management holds $362 million in CRISPR Therapeutics across two ETFs. While known for gene-editing work like the FDA-approved Casgevy, the company is quietly developing CAR T-cell therapies that could address a market projected to exceed $60 billion annually by 2034. CRISPR's off-the-shelf CAR T approach using donor cells could reduce costs compared to patient-specific treatments, positioning it competitively despite being in early trial stages.

07/22/2026, 5:30 AM • The Motley Fool

Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - Trends and Forecasts Till 2035

The global cancer biomarkers market is projected to grow from $25.9 billion in 2026 to $37.8 billion by 2035, with a CAGR of 4.3%. Growth is driven by rising cancer incidence, personalized medicine adoption, advances in NGS and liquid biopsy technologies, and increased biomarker-driven diagnostics. HER2 testing leads by biomarker type (21.1% share), while breast cancer testing dominates by indication (25.1% share). North America captures 52.1% of global market revenue.

07/22/2026, 4:49 AM • GlobeNewswire

Antiparasitic Drugs Market Report Released — Examines Antimalarials, Anthelmintics, Antiprotozoals, Ectoparasiticides, and Neglected Tropical Disease Therapies

The global antiparasitic drugs market is projected to grow from USD 23.30 billion in 2026 to USD 30.98 billion by 2032 at a 4.88% CAGR. Growth is driven by persistent parasitic disease burden, drug resistance, climate-sensitive vector transmission, and public health programs. Key opportunities include resistance-ready combination therapies, pediatric formulations, AI-enabled discovery, and diagnostics-linked prescribing, with Africa and Asia-Pacific leading endemic demand.

07/20/2026, 11:52 AM • GlobeNewswire

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

Novartis announced FDA traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary IgAN. The drug demonstrated a 48% reduction in eGFR decline versus placebo over two years in the Phase III APPLAUSE-IgAN study. Fabhalta is the first complement inhibitor approved for this indication and represents a significant advancement in treating this chronic autoimmune kidney disease.

07/16/2026, 7:02 PM • GlobeNewswire

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

07/15/2026, 11:00 AM • GlobeNewswire

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Novartis and Teva represent different pharmaceutical strategies: Novartis is a stable innovator with high margins and strong cash flow, while Teva is executing a turnaround from generics to biosimilars with improving profitability but higher debt. Despite Novartis's superior financial metrics, the article recommends Teva for long-term investors due to its more attractive valuation ratios and strong drug pipeline expected to drive growth in 2027.

07/09/2026, 12:12 PM • The Motley Fool

What Is the Vanguard International Dividend Appreciation ETF (VIGI), and Who Should Buy It?

The Vanguard International Dividend Appreciation ETF (VIGI) offers exposure to 343 global stocks from developed markets with a low 0.07% expense ratio, but has delivered underwhelming returns and a modest 2.13% dividend yield. The fund is heavily concentrated in Japan (30.9%) and Canada (23%), and has been significantly outperformed by the S&P 500 over its track record. Analysts suggest more diversified alternatives like the Vanguard International High Dividend Yield ETF (VYMI) may be better for long-term investors.

07/09/2026, 11:05 AM • The Motley Fool

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?

Vanguard Health Care ETF (VHT) offers broad diversification across 429 healthcare holdings with a low 0.09% expense ratio, while VanEck Pharmaceutical ETF (PPH) provides concentrated exposure to 26 drugmakers with higher returns but greater risk. VHT is more cost-effective and diversified, while PPH has delivered superior 5-year returns and higher dividend yield despite concentration risk and a higher 0.36% expense ratio.

07/09/2026, 8:15 AM • The Motley Fool

Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider

The transthyretin amyloidosis treatment market is projected to grow from USD 8.95 billion in 2025 to USD 35.10 billion by 2035 at a 14.64% CAGR. Growth is driven by increased ATTR-CM diagnosis rates, FDA approvals of gene-silencing therapies like vutrisiran and acoramidis, improved diagnostic imaging, and expanding pipeline therapies. North America dominates with 46% market share, while Asia Pacific is the fastest-growing region.

07/07/2026, 6:42 AM • GlobeNewswire

Brandon Capital Announces Agreement for Novartis to Acquire Portfolio Company Myricx Bio to Advance New Class of Cancer Therapeutics

Novartis has agreed to acquire Brandon Capital's portfolio company Myricx Bio for up to US$1.5 billion, including an upfront payment of US$1.1 billion plus milestone payments. Myricx Bio, a UK-based pre-clinical oncology company, has developed a novel class of N-myristoyltransferase inhibitor (NMTi) payloads for antibody-drug conjugates (ADCs) targeting solid tumors. The acquisition represents a significant exit for Brandon Capital and validates its early-stage investment in the breakthrough cancer therapeutic platform.

07/06/2026, 1:08 AM • GlobeNewswire

Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform

Novartis has agreed to acquire Myricx Bio for up to $1.5 billion ($1.1 billion upfront plus milestone payments) to advance next-generation antibody-drug conjugate (ADC) payloads using Myricx's novel N-myristoyltransferase inhibitor (NMTi) platform. The acquisition combines Novartis's oncology expertise with Myricx's differentiated ADC assets targeting solid tumors, addressing unmet needs in overcoming ADC resistance and improving tolerability.

07/06/2026, 1:05 AM • GlobeNewswire

Photodynamic Therapy Market: Durable Growth with a CAGR of 8.3% Through 2035

The global photodynamic therapy (PDT) market is expected to grow at a CAGR of 8.3% from 2023 to 2035, driven by minimally invasive treatment demand, expanding applications in oncology and dermatology, and technological innovations. North America is projected to grow at 14% CAGR, while Europe currently holds 50% market share. Over 70 PDT therapies are under clinical development, with challenges including limited tissue penetration and high system costs.

07/03/2026, 7:55 AM • GlobeNewswire